A Walk Through The AAD 2025 Poster Hall: The Must-See Research Shaping Dermatology

The poster hall at this year's Academy of Dermatology Annual Meeting showcased a wealth of innovative research and findings from across the specialty.

In this roundup, we’ve compiled the key takeaways from the posters and abstracts presented, offering you an inside look at the latest trends and developments. Explore full Dermatology Times coverage of the meeting here.

Almirall Showcases Therapeutic Innovations at AAD 2025

Almirall presented 5 scientific posters, highlighting new data on tirbanibulin for actinic keratosis (AK) and early-stage clinical findings on LAD191, a monoclonal antibody targeting IL-1RAP. Phase 3, 4, and real-world studies confirmed tirbanibulin’s high efficacy, favorable safety, and strong patient satisfaction, reinforcing its role as a reliable AK treatment.

Additionally, phase 1 data on LAD191 demonstrated a promising safety profile, supporting its potential in treating immune-mediated skin diseases.

Jeff Stark, MD: Reviewing UCB's Abstracts Across HS, PsO, PsA, and More

UCB presented 18 abstracts, including long-term data on bimekizumab (Bimzelx) for psoriasis and other approved indications such as hidradenitis suppurativa and psoriatic arthritis. A key highlight was the 5-year open-label extension study, demonstrating sustained efficacy with PASI 90 response rates in the upper 80% and PASI 100 in the mid-70%, reinforcing bimekizumab’s durability and safety.

Risankizumab Maintains High Skin Clearance Over 36 Months

Real-world data from the CorEvitas Psoriasis Registry highlighted the long-term efficacy of risankizumab in patients with moderate to severe plaque psoriasis. Among 179 patients treated continuously for 36 months, 96.2% achieved an acceptable response per NPF treatment goals, 84.2% met the target response, and 86.1% maintained PASI90 from 12 to 36 months. Additionally, 68.8% reported minimal impact on quality of life (DLQI 0/1).

Upadacitinib Shows Biomarker-Driven Efficacy in Nonsegmental Vitiligo

AbbVie presented phase 2 trial data on upadacitinib’s biomarker-driven effects in nonsegmental vitiligo. Findings showed that upadacitinib rapidly reduced CXCL9 and CXCL10—key type 1 inflammation markers—within 4 weeks, sustaining suppression through week 24. Simultaneously, melanocyte-associated proteins like Kit increased, correlating with repigmentation (VASI scores). By week 24, CXCL9/CXCL10 no longer correlated with VASI, reinforcing melanocyte biomarkers as better disease activity indicators.

Biologic-Naïve Patients with Psoriasis Have a Reduced Risk of Psoriatic Arthritis, Based on NPF Target Goals

AbbVie presented a real-world study from the CorEvitas Psoriasis Registry suggesting that achieving National Psoriasis Foundation (NPF) treatment goals with first-time biologic therapy may reduce the risk of psoriatic arthritis in patients with psoriasis. Among 1,352 biologic-naïve patients, those who met the NPF target goal (BSA ≤1%) within 3–15 months had a lower psoriatic arthritis incidence rate (6.46/100 PY) compared to those who did not (8.82/100 PY). Over 5 years, achieving the target was associated with a 27% reduced psoriatic arthritis risk (HR: 0.73, 95% CI: 0.55-0.96).

InflaRX Presents Efficacy and Safety Data on Vilobelimab at AAD 2025

InflaRx presented the 6 scientific posters on vilobelimab, highlighting its efficacy and safety in pyoderma gangrenosum and hidradenitis suppurativa. Phase 2a data confirmed vilobelimab’s safety in pyoderma gangrenosum, with a 90% reduction in C5a levels by day 15.

In the SHINE trial for hidradenitis suppurativa, vilobelimab reduced draining tunnels by 63.2% versus 18.0% with placebo, with a 3.1x improvement in dT100 response. Pharmacokinetic analyses showed sustained C5a suppression. Vilobelimab, a first-in-class C5a inhibitor, has orphan drug and fast-track designations, with phase 3 trials in pyoderma gangrenosum ongoing.

Reviewing 3 Key Lebrikizumab Abstracts From AAD 2025

Eli Lilly’s Anabela Cardoso, MD, presented new data on lebrikizumab’s long-term efficacy in atopic dermatitis. In the ADjoin extension study, 50% of patients maintained completely clear skin (IGA 0) at 3 years.

The ADapt study showed lebrikizumab’s efficacy in patients previously treated with dupilumab, with PNRS ≥4-point improvements in 53.2% and 61.5% at weeks 16 and 24.

The ADmirable study highlighted lebrikizumab’s benefits in skin of color, with 58.1% achieving PNRS ≥4-point improvement.

Read more on the ADjoin study: Lebrikizumab Shows 3-Year Sustained Efficacy in AD

Dupilumab Reduces Levels of Immunoglobulin E in Pediatric Patients with Moderate-to-Severe AD

One poster highlighted that dupilumab significantly reduced immunoglobulin E (IgE) levels in young children with moderate-to-severe atopic dermatitis. The LIBERTY AD PRESCHOOL trial showed a 70% reduction in IgE levels after 16 weeks of treatment. Age-stratified results demonstrated the most substantial decline in the youngest cohort (-84.9%). Given IgE’s link to atopic comorbidities, these findings suggest dupilumab may help mitigate allergic sensitization risks in pediatric patients with atopic dermatitis. Safety data remained consistent with prior reports.

Key Insights from Novartis at AAD and AAAAI: Flexibility and Personalization in Dermatology Treatment

At both AAD 2025 and AAAAI 2025, Novartis presented pivotal findings on the flexibility of secukinumab (Cosentyx) for hidradenitis suppurativa and the efficacy of remibrutinib in chronic spontaneous urticaria. Post-hoc analyses from the SUNSHINE and SUNRISE trials demonstrated that increasing Cosentyx dosing to every 2 weeks improved hidradenitis suppurativa outcomes in patients unresponsive to a 4-week schedule.

Meanwhile, phase 3 REMIX-1 and REMIX-2 data showed remibrutinib significantly reduced chronic spontaneous urticaria symptoms as early as week 1, with sustained benefits through week 52.

Which posters and abstracts did you find the most impactful? Share your thoughts with us by emailing our team at DTEditor@mmhgroup.com.